NLRP3 and colitis: The protective effects of TXM-CB13 in both DSS-induced colitis in mice and LPS-induced NLRP3 activation in RAW264.7 macrophages highlights a promising dual anti-inflammatory and antioxidant mechanisms, indicating its potential as a therapeutic candidate for inflammatory bowel disease.